Trastuzumab Recruiting Phase 1 Trials for Metastatic Breast Cancer (MBC) / Recurrent Breast Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02390427Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer